Independent commentary on peptide and research-compound science — drawn from the literature, the lab, and the researchers working with these compounds.
A new analysis in Diabetes, Obesity & Metabolism reports improvements across cardiovascular risk biomarkers in adults with obesity on retatrutide — with and without type 2 diabetes.
A systematic review examined GLP-1 receptor agonists in idiopathic intracranial hypertension — a signal that incretin research is expanding beyond metabolic outcomes.
A COA is a snapshot of what one laboratory measured on one sample. Understanding its limits is as important as reading its numbers.
Two identical-looking vials can come from different batches — and different batches can differ in ways a generic certificate will never reveal.
A batch of new NAD+ papers spans redox biology, cancer metabolism, and sirtuin signaling. The breadth is a reminder that NAD+ is a fundamental biochemistry topic, not just a supplement.
GHK-Cu is among the most widely discussed copper peptides. The interesting question is which of its effects are backed by human evidence and which remain preclinical.